GlassScriptPhysician profile
Heather L Bailey
NPI 1093768822
$6,173.98
in general payments reported to CMS, 2019-2025
33 companies · $2,649 in 2025
The $2,649 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $70.47 · 2022: $37.36 · 2023: $582 · 2024: $2,835 · 2025: $2,649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,844 · Education: $222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,843.91 |
| Education | $222.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $645.54 | 2023-2025 | |
| Abbott Laboratories | $608.09 | 2023-2025 | Jeti Peripheral Catheter, Perclose Prostyle, Esprit |
| Regeneron Healthcare Solutions, INC. | $551.21 | 2024-2025 | Dupixent |
| Dermavant Sciences, INC. | $456.16 | 2024 | Vtama |
| Janssen Biotech, INC. | $411.28 | 2024-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $383.68 | 2024-2025 | |
| Ucb, INC. | $337.84 | 2024-2025 | Bimzelx |
| Incyte Corporation | $281.82 | 2024-2025 | Opzelura, Opzelura |
| Pfizer INC. | $266.39 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $259.21 | 2024-2025 | Zoryve |
| Genzyme Corporation | $245.82 | 2024-2025 | |
| Galderma Laboratories, L.P. | $193.26 | 2024-2025 | Aklief |
| Botanix Sb INC | $176.54 | 2025 | Sofdra |
| Amgen INC. | $174.38 | 2023-2025 | Otezla, Otezla, Repatha |
| E.R. Squibb & Sons, L.L.C. | $173.76 | 2024-2025 | Sotyktu |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $169.13 | 2022-2024 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.54 | 2022-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $107.02 | 2024-2025 | |
| Novo Nordisk INC | $94.36 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Leo Pharma INC. | $87.15 | 2024-2025 | Adbry, Anzupgo |
| Sanofi-Aventis U.S. LLC | $79.99 | 2025 | |
| Merck Sharp & Dohme LLC | $46.44 | 2023 | Dificid, Gardasil 9 |
| Exact Sciences Corporation | $39.59 | 2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $35.90 | 2025 | Ebglyss, Taltz |
| Almirall LLC | $31.90 | 2024-2025 | Seysara, Klisyri |
| Biohaven Pharmaceuticals, INC. | $26.10 | 2021 | |
| Journey Medical Corporation | $25.03 | 2025 | |
| Inspire Medical Systems, INC. | $24.59 | 2023 | Inspire |
| Shield Therapeutics INC | $24.48 | 2024 | |
| Organon LLC | $21.95 | 2025 | Vtama |
| Glaxosmithkline, LLC. | $15.64 | 2023 | Bexsero, Shingrix, Arexvy |
| Btg International INC. | $15.13 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.06 | 2024 | Trulance, Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.